Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2021 ASCO Annual Meeting

• CME

American Cancer Society. Key statistics for esophageal cancer. cancer.org/cancer/esophagus-cancer/about/key-statistics.html. Accessed July 10, 2021.

Andre T, Shiu K-K, Kim TW, et al. Final overall survival for the phase III KEYNOTE-177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 3500.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.

Casak SJ, Marcus L, Fashoyin-Aje L, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res, 2021;[Epub ahead of print].

Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. Presented at: 2021 American Society for Clinical Oncology Virtual Meeting. Abstract LBA4001.

Fam-trastuzumab deruxtecan-nxki [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2021.

Janjigian Y, Kawazoe A, Yanez P, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study. Presented at: 2021 American Society for Clinical Oncology Virtual Meeting. Abstract 4013.

Janjigian Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.

Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 4003.

Le DT, Uram JN, Wan H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.

Moehler MH, Shitara K, Garrido M, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649. Presented at: 2021 American Society for Clinical Oncology Virtual Meeting. Abstract 4002.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®) for colorectal cancer v2.2021. www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed July 12, 2021. 

Nivolumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2021.

Pembrolizumab [prescribing information]. Whitehouse Station, NJ: Merck & Co.; 2021.

Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809-818.

Yoshino T, Di Bartolomeo M, Raghav KPS, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 3505.

Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598-5606.